PT Millennium Pharmacon International Tbk (SDPC.JK)
IDR 132.0
(0.76%)
IDR 132.0
(0.76%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 105.39 Billion IDR | 33.64% |
| 2022 | 73.96 Billion IDR | 28.1% |
| 2021 | 57.73 Billion IDR | 9.41% |
| 2020 | 52.77 Billion IDR | -18.52% |
| 2019 | 64.76 Billion IDR | 2.63% |
| 2018 | 63.1 Billion IDR | 27.95% |
| 2017 | 49.32 Billion IDR | 3.01% |
| 2016 | 47.87 Billion IDR | 12.65% |
| 2015 | 42.5 Billion IDR | 33.44% |
| 2014 | 31.85 Billion IDR | 10.17% |
| 2013 | 28.91 Billion IDR | 26.05% |
| 2012 | 22.93 Billion IDR | 35.09% |
| 2011 | 16.97 Billion IDR | 30.82% |
| 2010 | 12.97 Billion IDR | -56.02% |
| 2009 | 29.51 Billion IDR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 28.73 Billion IDR | -14.36% |
| 2024 Q2 | 29.91 Billion IDR | 11.12% |
| 2024 Q1 | 26.92 Billion IDR | 1.57% |
| 2023 Q1 | 21.83 Billion IDR | 25.37% |
| 2023 FY | 98.84 Billion IDR | 33.64% |
| 2023 Q4 | 26.5 Billion IDR | 27.63% |
| 2023 Q3 | 20.76 Billion IDR | -44.81% |
| 2023 Q2 | 37.62 Billion IDR | 72.34% |
| 2022 Q3 | 24.77 Billion IDR | 85.34% |
| 2022 Q4 | 17.41 Billion IDR | -29.71% |
| 2022 Q1 | 24.39 Billion IDR | 79.66% |
| 2022 FY | 73.96 Billion IDR | 28.1% |
| 2022 Q2 | 13.36 Billion IDR | -45.19% |
| 2021 Q2 | 13.25 Billion IDR | 14.14% |
| 2021 FY | 57.73 Billion IDR | 9.41% |
| 2021 Q4 | 13.57 Billion IDR | -29.62% |
| 2021 Q3 | 19.28 Billion IDR | 45.5% |
| 2021 Q1 | 11.61 Billion IDR | 96.42% |
| 2020 FY | 52.77 Billion IDR | -18.52% |
| 2020 Q4 | 5.91 Billion IDR | -51.76% |
| 2020 Q1 | 23.08 Billion IDR | 101.29% |
| 2020 Q2 | 11.51 Billion IDR | -50.15% |
| 2020 Q3 | 12.25 Billion IDR | 6.49% |
| 2019 Q2 | 18.85 Billion IDR | 7.67% |
| 2019 FY | 64.76 Billion IDR | 2.63% |
| 2019 Q1 | 17.5 Billion IDR | 13.53% |
| 2019 Q4 | 11.47 Billion IDR | -32.26% |
| 2019 Q3 | 16.93 Billion IDR | -10.17% |
| 2018 Q3 | 18.68 Billion IDR | 4.48% |
| 2018 FY | 63.1 Billion IDR | 27.95% |
| 2018 Q1 | 11.11 Billion IDR | -15.66% |
| 2018 Q2 | 17.88 Billion IDR | 60.93% |
| 2018 Q4 | 15.42 Billion IDR | -17.47% |
| 2017 FY | 49.32 Billion IDR | 3.01% |
| 2017 Q1 | 11.44 Billion IDR | -9.78% |
| 2017 Q2 | 11.8 Billion IDR | 3.19% |
| 2017 Q3 | 12.89 Billion IDR | 9.24% |
| 2017 Q4 | 13.17 Billion IDR | 2.17% |
| 2016 Q1 | 11.99 Billion IDR | -5.4% |
| 2016 FY | 47.87 Billion IDR | 12.65% |
| 2016 Q4 | 12.68 Billion IDR | 63.64% |
| 2016 Q3 | 7.74 Billion IDR | -49.83% |
| 2016 Q2 | 15.44 Billion IDR | 28.74% |
| 2015 Q2 | 10.86 Billion IDR | 22.78% |
| 2015 Q1 | 8.84 Billion IDR | -24.13% |
| 2015 FY | 42.5 Billion IDR | 33.44% |
| 2015 Q4 | 12.68 Billion IDR | 25.55% |
| 2015 Q3 | 10.1 Billion IDR | -7.02% |
| 2014 Q1 | 8.32 Billion IDR | -19.22% |
| 2014 FY | 31.85 Billion IDR | 10.17% |
| 2014 Q3 | 6.38 Billion IDR | 16.48% |
| 2014 Q2 | 5.48 Billion IDR | -34.11% |
| 2014 Q4 | 11.66 Billion IDR | 82.66% |
| 2013 Q3 | 7.02 Billion IDR | 28.12% |
| 2013 Q2 | 5.48 Billion IDR | -10.19% |
| 2013 Q4 | 10.29 Billion IDR | 46.61% |
| 2013 FY | 28.91 Billion IDR | 26.05% |
| 2013 Q1 | 6.1 Billion IDR | 1.53% |
| 2012 FY | 22.93 Billion IDR | 35.09% |
| 2012 Q3 | 4.85 Billion IDR | 0.0% |
| 2012 Q4 | 6.01 Billion IDR | 23.73% |
| 2011 FY | 16.97 Billion IDR | 30.82% |
| 2010 FY | 12.97 Billion IDR | -56.02% |
| 2009 FY | 29.51 Billion IDR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| PT Enseval Putera Megatrading Tbk. | 872.14 Billion IDR | 87.915% |
| PT Itama Ranoraya Tbk | 26.79 Billion IDR | -293.355% |
| PT Kimia Farma (Persero) Tbk | -1570.24 Billion IDR | 106.712% |
| PT Soho Global Health Tbk | 438.67 Billion IDR | 75.973% |